Rare clinical case: Autoimmune hepatitis type 3-Reference-Cited by-同舟云学术

Rare clinical case: Autoimmune hepatitis type 3

Published:2020-06-29 Issue:5 Volume:174 Page:120-126
ISSN:1682-8658
Container-title:Experimental and Clinical Gastroenterology
language:
Short-container-title:jour

Author:

Zharova M. E.¹^ORCID,Grigoreva Yu. V.²^ORCID,Nikonov E. L.³^ORCID,Ivanikov I. O.²^ORCID,Grebneva O. S.⁴

Affiliation:

1. N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; Research Institute for Healthcare Organization and Medical Management (a Government-funded Institution), Moscow City Department of Health

2. N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration

3. N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health

4. Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration

Abstract

Background. The fi rst clinical case of autoimmune hepatitis (AIH) was described in 1951, and in the 1970s, several randomized clinical trials proved the eff ectiveness of glucocorticosteroids in the treatment of AIH. Nonetheless, this disease remains a mystery to clinicians due to its rarity and heterogeneity. Aim. To describe the clinical case of the patient with AIH (SLA/LP antibodies) and discuss its management. Clinical case. A 22-year-old male with an acute manifestation of autoimmune hepatitis and a delayed, isolated increase of autoantibodies (SLA/LP). The initial diagnosis was made based on hypergammaglobulinemia and the eff ectiveness of glucocorticosteroids. Highly specifi c antibodies were detected only after 3.5 months, and the AIH was confi rmed histologically. Conclusion. This clinical case emphasizes the need to isolate type 3 AIH due to the more severe course and common relapse after the withdrawal of immunosuppressive therapy.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference15 articles.

1. Ivashkin VT, Bueverov AO, Maevskaya MV, Abdul ga nieva DI. Klinicheskie rekomendatsii po diagnostike i lecheniyu autoimmunnogo gepatita. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. 2013. Iva shkin V T, Bue ve rov AO, Mae vsk aya MV, Abdulganieva DI. Klinicheskie rekomendacii po diagnostike i lecheniyu autoimmunnogo gepatita. Ministerstvo zdravoohraneniya Rossijskoj Federacii. 2013.(In Russ.

2. Gleeson D, Heneghan MA, Gastroenterology BSo. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60(12):1611– 29. https://doi.org/10.1136/gut.2010.235259

3. Wiley-Blackwell. Yamada’s Textbook of Gastroenterology. 6 th Edition ed: Wiley; 2016:3440.

4. Odintsova A.Kh., Abdulganieva D. I., Cheremina N. A., Ibragimova A. V. Regional'nye kliniko-epidemiologicheskie osobennosti autoimmunnykh zabolevanii pecheni. Prakticheskaya meditsina. 2011;55:214–5. Odintsova A. H., Abdulganieva D. I., Cheremina N. A., Ibragimova A. V. Regional clinico-epidemiological features of autoimmune liver diseases. Prakticheskaya medicina.2011;55:214–5 (In Russ.)

5. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology. 1999;31(5):929–38. https://doi.org/10.1016/s0168-8278(99)80297-9